

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

HANNA et al.

Group Art Unit: 1644

Application Serial No. 09/772,938

Examiner: P. Gambel

Filed: January 31, 2001

Title: *TREATMENT OF CELL MALIGNANCIES USING COMBINATION  
OF B CELL DEPLETING ANTIBODY AND IMMUNE*

#6  
JW  
4/19/02

\* \* \* \* \*

ELECTION REPLY



Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement mailed on March 12, 2002, Applicants elect combined administration of an anti-CD40L antibody (as the immunomodulatory antibody) and an anti-CD20 antibody as the B cell depleting antibody for treatment of a B cell lymphoma, and specifically non-Hodgkin's disease.

Applicants presume that upon a determination that the elected species are patentable that the Examiner will broaden the search and examination to all B cell lymphomas and leukemias.

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

It is believed that this response is fully responsive to the outstanding Restriction Requirement. If the Examiner has any questions relating to this application he is respectfully requested to contact the undersigned.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Robin L. Teskin

Registration No. 35,030

1600 Tysons Boulevard  
McLean, Virginia 22102  
(703) 905-2000  
(703) 905-2500 Facsimile

Date: April 11, 2002  
Attorney Reference: 037003-0276658  
/af